Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Bismuth Versus Lactobacillus Reuteri for H. Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Positive for H. pylori infection~Exclusion Criteria:~* Presence of malignancy~* Pregnancy or lactation~* Clinically significant diseases~* History of drug or alcohol abuse~* Allergy to pantoprazole or to any component of regimens used in the study~* Use of anti-secretory drugs, antibiotics or probiotics 4 weeks preceding the enrollment.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- B.I.D. TMPPI + Lactobacillus-10 (Type: EXPERIMENTAL): pantoprazole 20 mg, tetracycline 500 mg, and metronidazole 500 mg twice a day supplemented with 1 capsule (2 x 108 CFU of L. reuteri DSM 17938 plus 2 x 108 CFU of L. reuteri ATCC PTA 6475) a day in the afternoon, given with the midday and evening meals for 10 days
- B.I.D. Bismuth (Type: ACTIVE_COMPARATOR): pantoprazole 20 mg and the same doses of antibiotics administered as tetracycline 250 mg, and metronidazole 250 mg plus 1 cp (140 mg bismuth subcitrate potassium, 125 mg metronidazole, and 125 mg tetracycline hydrochloride administered) x 2 all drugs twice-a-day given with the midday and evening meals for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).